XXXianyuan Xiang

Xianyuan Xiang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xianyuan Xiang has a total of 153 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Attenuation of Ca2+ signaling by overexpression of PMCA2 affects the microglial response to pathological events

    by Fan Zeng, Sagun Tiwari, Alaa Chok, Yan Zhou, Yue Zhao, Xuezhen Chen, Yue Hao, Kaichuan Zhu, Helmut Kettenmann, Xianyuan Xiang


  • Open Access

    Revisiting astrocytic calcium signaling in the brain

    by Ying Bai, Zhongqiu Zhou, Bing Han, Xianyuan Xiang, Wenhui Huang, Honghong Yao

    Astrocytes, characterized by complex spongiform morphology, participate in various physiological processes, and abnormal changes in their calcium (Ca2+) signaling are implicated in central nervous system disorders. However, medications targeting the control of Ca2+ have fallen short of the anticipated therapeutic outcomes in clinical applications. This underscores the fact that our comprehension of this intricate regulation of calcium ions remains considerably incomplete. In recent years, with the advancement of Ca2+ labeling, imaging, and analysis techniques, Ca2+ signals have been found to exhibit high specificity at different spatial locations within the intricate structure of astrocytes. This has ushered the study of Ca2+ signaling in astrocytes into a new phase, leading to several groundbreaking research achievements. Despite this, the comprehensive understanding of astrocytic Ca2+ signaling and their implications remains challenging area for future research.


  • Open Access

    TREM2 promotes glioma progression and angiogenesis mediated by microglia/brain macrophages

    by Xuezhen Chen, Yue Zhao, Yimin Huang, Kaichuan Zhu, Fan Zeng, Junyi Zhao, Huaqiu Zhang, Xinzhou Zhu, Helmut Kettenmann, Xianyuan Xiang

    Triggering receptor expressed on myeloid cell 2 (TREM2), a myeloid cell‐specific signaling molecule, controls essential functions of microglia and impacts on the pathogenesis of Alzheimer's disease and other neurodegenerative disorders. TREM2 is also highly expressed in tumor‐associated macrophages in different types of cancer. Here, we studied whether TREM2 influences glioma progression. We found a gender‐dependent effect of glioma growth in wild‐type (WT) animals injected with GL261‐EGFP glioma cells. Most importantly, TREM2 promotes glioma progression in male but not female animals. The accumulation of glioma‐associated microglia/macrophages (GAMs) and CD31+ blood vessel density is reduced in male TREM2‐deficient mice. A transcriptomic analysis of glioma tissue revealed that TREM2 deficiency suppresses immune‐related genes. In an organotypic slice model devoid of functional vascularization and immune components from periphery, the tumor size was not affected by TREM2‐deficiency. In human resection samples from glioblastoma, TREM2 is upregulated in GAMs. Based on the Cancer Genome Atlas Program (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases, the TREM2 expression levels were negatively correlated with survival. Thus, the TREM2‐dependent crosstalk between GAMs and the vasculature formation promotes glioma growth.


  • Open Access

    Versatile strategies for adult neurogenesis: avenues to repair the injured brain

    by Junyi Zhao, Siyu Liu, Xianyuan Xiang, Xinzhou Zhu

    Brain injuries due to trauma or stroke are major causes of adult death and disability. Unfortunately, few interventions are effective for post-injury repair of brain tissue. After a long debate on whether endogenous neurogenesis actually happens in the adult human brain, there is now substantial evidence to support its occurrence. Although neurogenesis is usually significantly stimulated by injury, the reparative potential of endogenous differentiation from neural stem/progenitor cells is usually insufficient. Alternatively, exogenous stem cell transplantation has shown promising results in animal models, but limitations such as poor long-term survival and inefficient neuronal differentiation make it still challenging for clinical use. Recently, a high focus was placed on glia-to-neuron conversion under single-factor regulation. Despite some inspiring results, the validity of this strategy is still controversial. In this review, we summarize historical findings and recent advances on neurogenesis strategies for neurorepair after brain injury. We also discuss their advantages and drawbacks, as to provide a comprehensive account of their potentials for further studies.


  • Response to Comment on “Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases”

    by Xianyuan Xiang, Sabina Tahirovic, Sibylle Ziegler, Christian Haass, Matthias Brendel

    Microglial FDG uptake alterations are the source of FDG-PET changes in models of neurodegenerative diseases.


  • Top Cited Papers

    Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases

    by Xianyuan Xiang, Karin Wind, Thomas Wiedemann, Tanja Blume, Yuan Shi, Nils Briel, Leonie Beyer, Gloria Biechele, Florian Eckenweber, Artem Zatcepin, et al.

    FDG-PET shows that microglial activation might drive cerebral glucose uptake in mice and patients with AD.


  • Open Access

    Pre-therapeutic microglia activation and sex determine therapy effects of chronic immunomodulation

    by Gloria Biechele, Tanja Blume, Maximilian Deussing, Benedikt Zott, Yuan Shi, Xianyuan Xiang, Nicolai Franzmeier, Gernot Kleinberger, Finn Peters, Katharina Ochs, et al.

    Modulation of the innate immune system is emerging as a promising therapeutic strategy against Alzheimer's disease (AD). However, determinants of a beneficial therapeutic effect are ill-understood. Thus, we investigated the potential of 18 kDa translocator protein positron-emission-tomography (TSPO-PET) for assessment of microglial activation in mouse brain before and during chronic immunomodulation.


  • Open Access

    The Alzheimer’s disease-associated protective Plcγ2-P522R variant promotes immune functions

    by Mari Takalo, Rebekka Wittrahm, Benedikt Wefers, Samira Parhizkar, Kimmo Jokivarsi, Teemu Kuulasmaa, Petra Mäkinen, Henna Martiskainen, Wolfgang Wurst, Xianyuan Xiang, et al.

    Background: Microglia-specific genetic variants are enriched in several neurodegenerative diseases, including Alzheimer’s disease (AD), implicating a central role for alterations of the innate immune system in the disease etiology. A rare coding variant in the PLCG2 gene (rs72824905, p.P522R) expressed in myeloid lineage cells was recently identified and shown to reduce the risk for AD. Methods: To assess the role of the protective variant in the context of immune cell functions, we generated a Plcγ2-P522R knock-in (KI) mouse model using CRISPR/Cas9 gene editing. Results: Functional analyses of macrophages derived from homozygous KI mice and wild type (WT) littermates revealed that the P522R variant potentiates the primary function of Plcγ2 as a Pip2-metabolizing enzyme. This was associated with improved survival and increased acute inflammatory response of the KI macrophages. Enhanced phagocytosis was observed in mouse BV2 microglia-like cells overexpressing human PLCγ2-P522R, but not in PLCγ2-WT expressing cells. Immunohistochemical analyses did not reveal changes in the number or morphology of microglia in the cortex of Plcγ2-P522R KI mice. However, the brain mRNA signature together with microglia-related PET imaging suggested enhanced microglial functions in Plcγ2-P522R KI mice. Conclusion: The AD-associated protective Plcγ2-P522R variant promotes protective functions associated with TREM2 signaling. Our findings provide further support for the idea that pharmacological modulation of microglia via TREM2-PLCγ2 pathway-dependent stimulation may be a novel therapeutic option for the treatment of AD.


  • Open Access

    The Trem2 R47H Alzheimer’s risk variant impairs splicing and reduces Trem2 mRNA and protein in mice but not in humans

    by Xianyuan Xiang, Thomas M. Piers, Benedikt Wefers, Kaichuan Zhu, Anna Mallach, Bettina Brunner, Gernot Kleinberger, Wilbur Song, Marco Colonna, Jochen Herms, et al.

    The R47H variant of the Triggering Receptor Expressed on Myeloid cells 2 (TREM2) significantly increases the risk for late onset Alzheimer’s disease. Mouse models accurately reproducing phenotypes observed in Alzheimer’ disease patients carrying the R47H coding variant are required to understand the TREM2 related dysfunctions responsible for the enhanced risk for late onset Alzheimer’s disease. A CRISPR/Cas9-assisted gene targeting strategy was used to generate Trem2 R47H knock-in mice. Trem2 mRNA and protein levels as well as Trem2 splicing patterns were assessed in these mice, in iPSC-derived human microglia-like cells, and in human brains from Alzheimer’s patients carrying the TREM2 R47H risk factor. Two independent Trem2 R47H knock-in mouse models show reduced Trem2 mRNA and protein production. In both mouse models Trem2 haploinsufficiency was due to atypical splicing of mouse Trem2 R47H, which introduced a premature stop codon. Cellular splicing assays using minigene constructs demonstrate that the R47H variant induced abnormal splicing only occurs in mice but not in humans. TREM2 mRNA levels and splicing patterns were both normal in iPSC-derived human microglia-like cells and patient brains with the TREM2 R47H variant. The Trem2 R47H variant activates a cryptic splice site that generates miss-spliced transcripts leading to Trem2 haploinsufficiency only in mice but not in humans. Since Trem2 R47H related phenotypes are mouse specific and do not occur in humans, humanized TREM2 R47H knock-in mice should be generated to study the cellular consequences caused by the human TREM2 R47H coding variant. Currently described phenotypes of Trem2 R47H knock-in mice can therefore not be translated to humans.


  • Open Access

    Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibition Impairs Synaptic Plasticity via Seizure Protein 6

    by Kaichuan Zhu, Xianyuan Xiang, Severin Filser, Petar Marinković, Mario M. Dorostkar, Sophie Crux, Ulf Neumann, Derya R. Shimshek, Gerhard Rammes, Christian Haass, et al.